AbbVie sees Rinvoq, Skyrizi combined sales eclipsing Humira peak sales (NYSE:ABBV)

Rate this post


Although AbbVie’s blockbuster treatment Humira (adalimumab) will see biosimilar competition this year, the company expects that Rinvoq (upadacitinib) and Skyrizi (risankizumab) will eventually see higher combined peak sales than at Humira’s peak.

Speaking at the JP Morgan Healthcare

Authore – Abhi bhardwaj

Hello friends, my Abhi Bhardwaj I am the owner of and I am also a student. recently I just completed my graduation I am doing blogging since 2020 I love to write and always love exploring, and sharing knowledge with others that is why I started this blog basically this blog is related to us stock market, real estate, insurance, crypto, finance and tax if you have any qouri then please don't be shy

Sharing Is Caring:

Leave a Comment